Dogwood Therapeutics (DWTX) Registration Filing summary

Company overview and business model

• Focuses on developing new medicines for pain and fatigue-related disorders, with lead programs in non-opioid analgesics and antiviral therapies targeting herpes virus-mediated illnesses.

• Lead candidate Halneuron® is in Phase 2b clinical trials for chemotherapy-induced neuropathic pain, using a sodium channel modulator derived from marine sources.

• Pipeline includes IMC-1 and IMC-2, fixed-dose antiviral combinations for fibromyalgia and Long-COVID, with ongoing efforts to secure development partners.

• Recently licensed SP16 IV, a neural repair and anti-inflammatory agent, for potential use in combination with Halneuron®.

Financial performance and metrics

• Pre-revenue, development-stage company with no commercialized products as of the filing date.

• Audited financials for 2023 and 2024 included in the Annual Report, with a going concern warning from auditors.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of shares by selling stockholders; proceeds go directly to selling stockholders.

• Responsible for certain offering fees and expenses related to registration.